The warning affects all treatments containing GLP-1 receptor agonists, including semaglutide ( Ozempic, Wegovy, Rybelsus ), ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Coverage for these medications varies widely across plans; while many employers cover GLP-1 for diabetes treatment, fewer ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

The analysis used health data from the Rochester Epidemiology Project collected from 2000 to 2022. The first GLP-1 medication was prescribed beginning in 2006, and the authors included cases beginning ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

It can be harder to lose weight after a certain age, which is why GLP-1 medications can be incredibly useful. That's where ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Smoothie King, a franchise that specializes in selling smoothies, recently launched a "GLP-1 Support Menu," made specifically ...